Richard young 2023

Richard Young

Managing Director and Principal Toxicologist

Qualifications

BSc in Marine Biology & Coastal Ecology

MSc in Applied Toxicology

UK Registered Toxicologist (UKRT)

European Registered Toxicologist (ERT)

Richard Young,
Managing Director and Principal Toxicologist

Qualifications and Experience

Richard has over 20 years’ experience in desk-based toxicology at bibra. In 2018, Richard became the Managing Director of bibra, after taking over from James (who still remains a Toxicology Director and Chairman).

Richard has worked for clients from the food and beverage, food contact materials, consumer goods, agrochemical, biocidal, industrial chemical, pharmaceutical, electronic cigarette and cannabinoid sectors. For the past 15 years, he has been heavily involved in assisting companies comply with their REACH registration obligations, including supporting registrants respond to ECHA Evaluation decisions. 

Richard has played a key role in assisting e-cigarette and e-liquid manufacturers and importers with the toxicological assessments of their products, notably with their EU TPD and US FDA PMTA compliance obligations. Most recently he has been involved in the toxicological assessment of cannabinoids (notably CBD and THC) for a number of clients from a range of sectors (e.g. food, consumer products and pharmaceuticals). 

Qualifications and Experience 

Richard has an MSc in Applied Toxicology and is a RSB/BTS and European Registered Toxicologist (ERT). 

His skills include expert analysis of human health data. This can involve the pragmatic application of risk assessment methodology to mammalian toxicity data sets in order to derive robust conclusions on toxicological acceptability and health risks to exposed populations.

Areas of Expertise

Hobbies and Interests 

In his spare time Richard can be found playing padel tennis and 5-a-side football (when his knees can cope), and running around and entertaining his two children.

Richard's case studies and blog posts

EU Potential Changes to TPD

Blog articles

In April 2026, the European Commission published its evaluation of the Tobacco Products Directive and Tobacco Advertising Directive (TPD) and Tobacco Advertising Directive (TAD). The evaluation concluded that, while the existing framework has made a positive contribution to the protection of public health, it is increasingly challenged by the emergence and growing use of novel tobacco and nicotine products.

FDA memoranda: genotoxicity and carcinogenicity assessments of ENDS

Blog articles

As discussed in a previous blog post, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has issued several “scientific policy memoranda” that provide some great insights into the Agency’s evaluation process. In June 2024, the FDA made two new memos available that relate to the genotoxicity and carcinogenicity assessment of chemical constituents of Electronic Nicotine Delivery Systems (ENDS).

FDA memoranda: shedding light on health risk assessment of ENDS in PMTA submissions

Blog articles

In 2016, the United States (US) Food and Drug Administration (FDA) ruled that Electronic Nicotine Delivery Systems (ENDS) were to be regulated just like more traditional tobacco products, meaning that ENDS (e-cigarettes and e-liquids) are subject to premarket review requirements, despite containing no tobacco. ENDS manufacturers must therefore submit a Premarket Tobacco Product Application (PMTA) to the FDA Center for Tobacco Products (CTP) in order to have any chance of legally marketing their products in the US.

Want to read more case studies and blog posts that Richard has been involved in? Click below to read more.

Contact us